Thus, the use of combination pharmacotherapy involving other molecules in addition to gut hormones seems to be a plausible approach to treating the metabolic syndrome
We excluded patients with type 1 diabetes, eGFR 10 years), body mass index ( 90, 6090, 4560, 3045, and 1530 mL/min/1.73 m 2 )
Dulaglutide is an injectable medication associated with good glycemic control and weight loss in patients with type 2 diabetes and has been previously shown to be effective in Japanese populations specifically [19]
Tirzepatide exhibits several clinically significant drug interactions that healthcare providers must carefully consider when prescribing this medication to ensure therapeutic efficacy and patient safety
This material is not approved for human or veterinary use and is not sold as a therapeutic, supplement, cosmetic, or food product